Views & Analysis | Perspectives on pharma industry issues

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Market Access

Sponsored

The pre-commercial case for connecting data before acquiring...

For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.

Articles

Rare disease perspectives from patients and caregivers

Have you ever wondered what it must be like to live with a rare disease as a patient or caregiver? Watch our video to hear some first-hand accounts. We spoke with several rare disease patients and caregivers and asked them to share their personal experiences with us...

Articles

Editor’s Voice: February – rare disease awareness and top te...

Take a look at what’s been happening on pharmaphorum this month, from our rare disease and patient content, to our top ten e-patients nominations to our rare disease patient video. If we can say so ourselves, what a fantastic month it’s been on pharmaphorum. Our disease focus this month has been...

Articles

Pharma news highlights: GSK, Lilly, the FDA and more

Ed Silverman discusses the latest pharma developments, from GSK’s signing of the AllTrials campaign, to the FDA’s recent lawsuit decisions, to Lilly’s patent losses in Canada. And so, another month has passed that was brimming with interesting developments in the pharmaceutical world. One story, in particular, gained...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital